Resource Logo
NLM AIDSLINE

Rapid decline of naturally acquired antibody to hepatitis B surface antigen (AntiHBs) and HBV reactivation in AbHIV+ I.V. drug users (IVDUs).




 

Int Conf AIDS. 1990 Jun 20-23;6(2):213 (abstract no. F.B.540). Unique

OBJECTIVES: To evaluate the behaviour of antiHBs titre in HIV+IVDUs. METHODS: We studied for 4 yrs. the antiHBs titre of 134 HIV+IVDUs. We compared the antiHBs titres' changes of 30 HIV+IVDUs (none of them ARC or AIDS; antiHBs greater than 10 less than 500 IU/1; CD4+ greater than 400/ml) with those of 31 HIV-IVDUs similar in ages, duration of intravenous drug use, antiHBs levels. RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. 65 HIV+IVDUs (48.5%), where initial antiHBs mean titre was 105+96 IU/1, at the end had an antiHBs titre less than 10 IU/1. In 4 (3 AIDS, 1 ARC) HBsAg reappeared (in 2 we found also HBeAg and HBV DNA; none showed signs of acute hepatitis). CONCLUSIONS: The decline of antiHBs titre in HIV+IVDUs, even in the early stages of HIV infection, is faster than in HIV-IVDUs. By contrast, only a deep immunodeficiency elicited the HBsAg reappearance.

Hepatitis B/COMPLICATIONS/*IMMUNOLOGY Hepatitis B Antibodies/*BIOSYNTHESIS Hepatitis B Surface Antigens/*IMMUNOLOGY Hepatitis B Virus/GROWTH & DEVELOPMENT Human HIV Infections/*COMPLICATIONS *Substance Abuse, Intravenous Virus Activation ABSTRACT



 




Information in this article was accurate in December 30, 1990. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.